Copyright  2017 Advantagene, Inc.  All rights reserved. Made by AFP.    Terms of use | Privacy policy

Malignant Pleural Effusion is estimated by the American Cancer Society to affect more than 150,000 individuals per year in the United States. The condition causes severe shortness of breath and chest pain, most often due to lung cancer and mesothelioma, and also advanced breast cancer, ovarian cancer and lymphoma. Once a malignant pleural effusion is diagnosed, the prognosis is very poor with patients living just four more months on average.


We have completed enrollment in an additional Phase I study of intrapleural AdV-tk therapy in patients with malignant pleural effusion (MPE). The primary objective is to test the safety of intrapleural AdV-tk therapy. Secondary objectives are to evaluate clinical efficacy and biologic activity.  The goal of this open-label, dose escalation clinical trial is to investigate if the administration of GMCI to patients with MPE followed by chemotherapy is safe, can be effectively delivered without disturbing standard therapy, and will have anti-tumor activity.  



Principal Investigator

Charu Aggarwal, MD

Assistant Professor of Medicine

University of Pennsylvania  

  




 

For more information on this study , Click

Clinicaltrials.gov

Malignant Pleural Effusion/Mesothelioma